Westshore Wealth LLC Boosts Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Westshore Wealth LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 17.9% during the 2nd quarter, Holdings Channel reports. The firm owned 2,589 shares of the medical research company’s stock after buying an additional 394 shares during the period. Westshore Wealth LLC’s holdings in Edwards Lifesciences were worth $246,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its stake in shares of Edwards Lifesciences by 14.6% during the 1st quarter. Lindbrook Capital LLC now owns 738 shares of the medical research company’s stock worth $87,000 after acquiring an additional 94 shares during the last quarter. Hoylecohen LLC lifted its holdings in shares of Edwards Lifesciences by 1.0% in the 1st quarter. Hoylecohen LLC now owns 9,923 shares of the medical research company’s stock valued at $1,168,000 after buying an additional 100 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in shares of Edwards Lifesciences by 18.6% in the 1st quarter. Pinnacle Bancorp Inc. now owns 701 shares of the medical research company’s stock valued at $83,000 after buying an additional 110 shares during the period. TPG Financial Advisors LLC increased its stake in shares of Edwards Lifesciences by 2.9% in the 1st quarter. TPG Financial Advisors LLC now owns 4,109 shares of the medical research company’s stock valued at $484,000 after purchasing an additional 115 shares in the last quarter. Finally, American National Bank increased its stake in Edwards Lifesciences by 99.1% during the 1st quarter. American National Bank now owns 233 shares of the medical research company’s stock worth $27,000 after buying an additional 116 shares in the last quarter. Institutional investors and hedge funds own 81.33% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $84.17, for a total value of $1,672,878.75. Following the transaction, the chief executive officer now directly owns 157,353 shares in the company, valued at $13,244,402.01. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $84.17, for a total value of $1,672,878.75. Following the sale, the chief executive officer now directly owns 157,353 shares in the company, valued at approximately $13,244,402.01. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction that occurred on Friday, July 8th. The shares were sold at an average price of $97.60, for a total transaction of $656,360.00. Following the completion of the transaction, the vice president now owns 62,561 shares of the company’s stock, valued at approximately $6,105,953.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 86,128 shares of company stock worth $8,223,839. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW traded down $0.12 during midday trading on Friday, hitting $84.05. The company had a trading volume of 83,497 shares, compared to its average volume of 2,660,012. Edwards Lifesciences Co. has a twelve month low of $83.42 and a twelve month high of $131.73. The firm’s 50-day simple moving average is $97.39 and its 200-day simple moving average is $101.83. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.60 and a current ratio of 3.37. The company has a market capitalization of $52.11 billion, a PE ratio of 36.44, a P/E/G ratio of 2.52 and a beta of 1.14.

Edwards Lifesciences (NYSE:EWGet Rating) last released its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the previous year, the business earned $0.64 EPS. The firm’s revenue was down .2% compared to the same quarter last year. Equities research analysts predict that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on EW shares. Cowen dropped their price target on Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 17th. Cowen reduced their price objective on Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. Canaccord Genuity Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the company from $115.00 to $106.00 in a report on Friday, July 29th. Finally, Truist Financial dropped their price objective on Edwards Lifesciences from $117.00 to $112.00 and set a “buy” rating on the stock in a report on Thursday. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.81.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

See Also

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.